Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Q3 2024 Earnings Presentation
17 slides from Invivyd's earnings presentation, Nov 14, 2024
Slide 1: Invivyd Q3 2024 Financial Results & Business Highlights
Exhibit 99.2 INVIVYD Q3 2024 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS November 14, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Trial: Month Data Update u Pipeline u Commercial Update Finance Q&A 3
u Executive Summary u CANOPY Phase 3 Clinical Trial: 12 Month Data Update u Pipeline u Commercial Update Finance Q&A 3
Slide 4: A Quarter of High Engagement Despite Unexpected Fact Sheet Headwind
A QUARTER OF HIGH ENGAGEMENT DESPITE UNEXPECTED FACT SHEET HEADWIND; POSITIONED FOR RETURN TO GROWTH • CANOPY exploratory clinical efficacy data, to date, reconfirm a high level of risk reduction from developing symptomatic COVID-19 in immunocompetent participants (84% RRR months 1-6, and 64% RRR mo
Slide 5: Trial: Month Data Update Pipeline Commercial Update Finance Q&A 5
u Executive Summary u CANOPY Phase 3 Clinical Trial: 12 Month Data Update Pipeline Commercial Update Finance Q&A 5
Slide 6: PEMGARDA Demonstrated Continued Protection During Off-Drug Period
PEMGARDA DEMONSTRATED CONTINUED PROTECTION DURING OFF-DRUG PERIOD • Strong protection observed over multiple waves and lineages of SARS- CoV-2, including 6-month data from a JN.1 dominant wave during active dosing (84% RRR vs. placebo in Cohort B) • Protection continued during long-term wash-out (mo
Slide 7: Trial: Month Data Update u Pipeline Commercial Update Finance Q&A 7
u Executive Summary u CANOPY Phase 3 Clinical Trial: 12 Month Data Update u Pipeline Commercial Update Finance Q&A 7
Slide 8: Next Up: VYD2311, a mAb with High In Vitro Potency
NEXT UP: VYD2311, A MAB WITH HIGH IN VITRO POTENCY SHOWN AGAINST POST-OMICRON COVID-19 VARIANTS TESTED TO DATE Our next-generation mAb, VYD2311, improves biophysical properties; shows continued in vitro neutralization activity in pseudovirus assays against KP1.1 FLiRT, KP.2 FLiRT, KP.3, KP.3.1.1 and
Slide 9: Trial: Month Data Update u Pipeline u Commercial Update Finance Q&A 9
u Executive Summary u CANOPY Phase 3 Clinical Trial: 12 Month Data Update u Pipeline u Commercial Update Finance Q&A 9
Slide 10: COVID-19 Presents a Clear Danger Today
COVID-19 PRESENTS A CLEAR DANGER TODAY 1* Hospitalizations Deaths 2* COVID-19 656,739 58,502 3* Influenza 278,637 10,454 4† RSV 184,530 ≈6,000–10,000 COVID-19=coronavirus disease 2019; RSV=respiratory syncytial virus. *From Oct 7, 2023, through September 28, 2024; ≈58,502 Americans died from COVID-1
Slide 11: COVID-19 Continues to Drive ICU Admissions
COVID-19 CONTINUES TO DRIVE ICU ADMISSIONS ICU = Intensive Care Unit Hospitalization data based on calculations completed by Invivyd. Hospitalizations calculated based on 334.9 million U.S. Census Bureau estimate of U.S. population size. † From October 7, 2023, through September 28, 2024. Reference:
Slide 12: COVID-19 Continues to Lead to Long-Term Systemic Damage
COVID-19 CONTINUES TO LEAD TO LONG-TERM SYSTEMIC DAMAGE NEUROLOGIC CARDIAC • Cerebrovascular disorders • MI (types I & II) • Corticospinal damage • Heart failure • Meningitis/encephalitis • Viral myocarditis • Encephalopathy • Stress cardiomyopathy • Cognitive + motor deficits • Arrhythmia SYSTEMIC
Slide 13: Poised for Acceleration and Growth
13 POISED FOR ACCELERATION AND GROWTH Initiatives for Growth Q4 into 2025 • Anticipated Tail Winds from COVID-19 Seasonal • Headwinds created by August Fact Sheet Spike with the Holidays and Indoor Gatherings Update o Caused 30 days of confusion • Investing in Direct Hire Resources • Developing Infu
Slide 14: Key Launch Metrics Showing Expanded Commercial Coverage
KEY LAUNCH METRICS SHOWING EXPANDED COMMERCIAL COVERAGE As of July 31 As of Aug 31 As of Sept 30 As of Oct 31 HCP Interactions 2,032 2,698 3,198 3,722 Logged Unique Accounts 911 1,099 1,216 1,365 Called On Unique Accounts 208 274 347 426 Ordered • Breadth of clinician and patient experience with new
Slide 15: Trial: Month Data Update u Pipeline u Commercial Update u Finance Q&A 15
u Executive Summary u CANOPY Phase 3 Clinical Trial: 12 Month Data Update u Pipeline u Commercial Update u Finance Q&A 15
Slide 16: Financials
FINANCIALS • Q3 2024 PEMGARDA (pemivibart) net product revenue of $9.3 million • Ended Q3 2024 with approximately $106.9 million in cash and cash equivalents • Targeting near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various
Slide 17: Trial: Month Data Update u Pipeline u Commercial Update u Finance u Q&A 17
u Executive Summary u CANOPY Phase 3 Clinical Trial: 12 Month Data Update u Pipeline u Commercial Update u Finance u Q&A 17